Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more
Market Cap & Net Worth: Oramed Pharmaceuticals Inc (ORMP)
Oramed Pharmaceuticals Inc (NASDAQ:ORMP) has a market capitalization of $143.69 Million ($143.69 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18020 globally and #6772 in its home market, demonstrating a 10.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oramed Pharmaceuticals Inc's stock price $3.61 by its total outstanding shares 39802455 (39.80 Million).
Oramed Pharmaceuticals Inc Market Cap History: 2015 to 2026
Oramed Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $340.31 Million to $143.69 Million (-6.38% CAGR).
Index Memberships
Oramed Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #495 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1675 of 3165 |
Weight: Oramed Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oramed Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oramed Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
68.61x
Oramed Pharmaceuticals Inc's market cap is 68.61 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
16.64x
Oramed Pharmaceuticals Inc's market cap is 16.64 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $243.59 Million | $641.00K | -$10.96 Million | 380.02x | N/A |
| 2017 | $358.22 Million | $2.46 Million | -$10.48 Million | 145.86x | N/A |
| 2018 | $119.41 Million | $2.45 Million | -$12.73 Million | 48.76x | N/A |
| 2019 | $204.98 Million | $2.70 Million | -$14.36 Million | 75.84x | N/A |
| 2020 | $168.76 Million | $2.71 Million | -$11.51 Million | 62.27x | N/A |
| 2021 | $568.38 Million | $2.70 Million | -$22.24 Million | 210.28x | N/A |
| 2022 | $478.82 Million | $2.70 Million | -$37.76 Million | 177.15x | N/A |
| 2023 | $91.94 Million | $1.34 Million | $5.53 Million | 68.61x | 16.64x |
Competitor Companies of ORMP by Market Capitalization
Companies near Oramed Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Oramed Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oramed Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Oramed Pharmaceuticals Inc's market cap moved from $340.31 Million to $ 143.69 Million, with a yearly change of -6.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $143.69 Million | +26.67% |
| 2025 | $113.44 Million | +17.77% |
| 2024 | $96.32 Million | +4.76% |
| 2023 | $91.94 Million | -80.80% |
| 2022 | $478.82 Million | -15.76% |
| 2021 | $568.38 Million | +236.79% |
| 2020 | $168.76 Million | -17.67% |
| 2019 | $204.98 Million | +71.67% |
| 2018 | $119.41 Million | -66.67% |
| 2017 | $358.22 Million | +47.06% |
| 2016 | $243.59 Million | -28.42% |
| 2015 | $340.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Oramed Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $143.69 Million USD |
| MoneyControl | $143.69 Million USD |
| MarketWatch | $143.69 Million USD |
| marketcap.company | $143.69 Million USD |
| Reuters | $143.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.